Please login or create an account. If you do not have access to this content, you will be shown a 30 second preview and licensing options.
- Presentation
New Drugs, New Rashes: An Update on Cutaneous Drug Eruptions
Description
In a session led by dermatologist Sue Bergen, experts discussed the evolving landscape of drug-induced hypersensitivity syndrome (DRESS), previously known as drug reaction with eosinophilia and systemic symptoms. Dr. Pasheka outlined key diagnostic features and notable clinical pearls regarding DRESS, emphasizing the challenges in identifying its varied manifestations in patients. A case study highlighted a patient who developed DRESS after being treated with trimethoprim-sulfamethoxazole, showcasing the spectrum of rashes associated with the syndrome. The presentation shed light on the importance of thorough patient history, particularly regarding the latency periods of different drugs, including the unexpectedly shorter latency of vancomycin. The session also discussed the raised risk of future autoimmune diseases in patients who have survived DRESS and the need for ongoing surveillance beyond the initial recovery phase. Participants were encouraged to consider the potential impact of therapeutic interventions like IVIG and the utility of scoring systems to identify individuals at higher risk of developing subsequent autoimmune disorders. The session concluded with recommendations for increased awareness among healthcare providers and provided resources for patients affected by DRESS.
View moreConclusions
- Drug Induced Hypersensitivity Syndrome (DRESS) is increasingly recognized and requires updated diagnostic and surveillance practices.
- DRESS can manifest with diverse skin rashes and symptoms, complicating diagnosis and treatment.
- An oblique earlobe crease may serve as a novel physical marker for diagnosing DRESS with high sensitivity and specificity.
- Vancomycin is associated with a shorter latency period for DRESS compared to other drugs, emphasizing the need for careful monitoring.
- Patients with DRESS are at increased risk for future autoimmune diseases, necessitating ongoing surveillance.
- Risk profiling, notably for HLA-A*32:01 in European ancestry patients, could inform pre-screening for DRESS risks.
- Current research suggests that the risk of future autoimmune disease is heightened specifically for DRESS compared to other severe cutaneous adverse reactions.
- Gilkey TW, Amigo MA, Himed S et al. Oblique ear- lobe crease as a novel physical examination finding in drug reaction with eosinophilia and systemic symptoms: a retrospective study. J Eur Acad Dermatol Venereol 2022; 36: e739-e740. https://doi.org/10.1111/jdv.18270
- Ushigome Y, Kano Y, Ishida T, Hirahara K, Shiohara T. Short- and long-term outcomes of 34 patients with drug-induced hypersensitivity syndrome in a single institution. J Am Acad Dermatol. 2013;68(5):721-728. doi:10.1016/j.jaad.2012.10.017
- Kano Y, Tohyama M, Aihara M, et al. Sequelae in 145 patients with drug-induced hypersensitivity syndrome/drug reaction with eosinophilia and systemic symptoms: survey conducted by the Asian Research Committee on Severe Cutaneous Adverse Reactions (ASCAR). J Dermatol. 2015;42(3):276-282. doi:10.1111/1346-8138.12770
- Mizukawa Y, Aoyama Y, Takahashi H, Takahashi R, Shiohara T. Risk of Progression to Autoimmune Disease in Severe Drug Eruption: Risk Factors and the Factor-Guided Stratification. J Invest Dermatol. 2022;142(3 Pt B):960-968.e9. doi:10.1016/j.jid.2021.11.008